#1CYTEK TRANSCEND THE CONVENTIONAL Corporate Presentation 2024 J.P. Morgan Healthcare Conference January 11, 2024 Dr. Wenbin Jiang, CEO Patrik Jeanmonod, CFO Paul Goodson, Investor Relations#2Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding Cytek's expected revenue for the full year ended December 31, 2023; Cytek's business and operational goals and strategies; Cytek's business development plans; Cytek's estimated market size and opportunities; Cytek's prospective products; objectives of management for future operations; and the expected key strategic benefits from the flow cytometry and imaging business acquired from Luminex. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, and financial needs. All statements other than statements of historical facts contained in this presentation, including, without limitation, statements The words "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks relating to adjustments to the revenue estimate that may be required in connection with the completion of the Company's year-end closing and auditing procedures; global economic and market conditions; Cytek's ability to evaluate its prospects for future viability and predict future performance; Cytek's ability to accurately forecast customer demand and adoption of its products; Cytek's ability to successfully integrate the acquired Luminex business and recognize the anticipated benefits of the transaction; Cytek's dependence on certain sole and single source suppliers; competition; market acceptance of Cytek's current and potential products; Cytek's ability to manage the growth and complexity of its organization, maintain relationships with customers and suppliers and retain key employees; Cytek's ability to maintain, protect and enhance its intellectual property; and Cytek's ability to continue to stay in compliance with its material contractual obligations, applicable laws and regulations. Information on these and additional risks and uncertainties and other information affecting Cytek's business and operating results is contained in Cytek's Quarterly Report on Form 10-Q for the quarter ended November 14, 2023, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Except as required by applicable law, Cytek does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. Certain information contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and Cytek's internal estimates and research. While Cytek believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Cytek believes its internal research is reliable, such research has not been verified by any independent source. Cytek's estimates are derived from publicly available information, management's knowledge of the Cytek's industry and management's assumptions based on such information and knowledge, which they believe to be reasonable. This data involves a number of assumptions and limitations which are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. This presentation includes certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the twelve months ended September 30, 2023. Management believes that non-GAAP financial measures, including "Adjusted EBITDA", taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP measures to compare the company's performance relative to forecasts and strategic plans and to benchmark the company's performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company's operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the tables accompanying this presentation. Cytek, Full Spectrum Profiling, FSP, Northern Lights, Cytek Aurora, cFluor, Tonbo, Amnis, Guava, Muse, ImageStream, Flow Sight, CellStream and easyCyte are trademarks of Cytek Biosciences, Inc. Other trademarks appearing in this presentation are the property of their respective holders. CYTEK TRANSCEND THE CONVENTIONAL N#3Instruments Performance Our Foundational Four Business Pillars Intelligence Ease of Use Compact Cost Effective Instruments CYTEK TRANSCEND THE CONVENTIONAL Applications Applications Enabler Panels/Kits Bioinformatics Flexibility Functionality Recurring Clinical Bioinformatics Storage Analysis / Al Optimization Management Exchanges Clinical Regulatory LDT Menu Driven AI Standardization 3#4Cytek at a Glance (as of Q3-2023) (1) Broad Customer Base and Global Presence Validated Technology Platform 1,997 Cytek FSP Units Placed 1,450+ Cytek FSP Peer- reviewed Publications CYTEK TRANSCEND THE CONVENTIONAL 1,500+ Customers 70+ Countries Trailing 12 months as of (9/30/2023) Strong Financial Profile 1. As of Q3'23 2. Acquired from Luminex in February 2023 3. Announced partnership with Bio-Rad for use of StarBright dye portfolio in February 2023 4. Acquired from Tonbo in November 2021 5. Preliminary and unaudited; estimate as of January 8, 2024 $183.1M $9.3M TTM Revenue/ A-EBITDA $288M Net Cash/Equivalent 2023 Outlook Revenue for the full year 2023 expected to be near the high-end of the $188 - $192M guidance range (5) Productive R&D and BusDev Engine Cytek Orion Amnis & Guava (2) StarBright Reagents (3) CE-IVDD Tonbo Reagents (4) Cell Sorter cFluor Reagents Northern Lights Cytek Aurora Athena 2023 2023 2023 2022 2021 2021 2020 2018 2017 2016 4#5Cytek Aurora Cell Sorter Platform of Cytek Cell Analysis Solutions Amnis & Guava Violet Specificity CD3 CD14 CD45 ZEE LINK Fluorochrome cFluor V420 cFluor V450 cFluor V547 CYTEK TRANSCEND THE CONVENTIONAL Northern Lights Specificity CD8 CCR7 IgD CD45RA CD19 CD25 Automatic sample loader Blue Athena Fluorochrome cFluor 8515 cFluor BYG575 cFluor BYG667 cFluor B690 cFluor BYG710 cFluor BYG781 Specificity CD127 CD16 CD56 CD4 Viability CD27 Red Cytek Orion Fluorochrome cFluor R659 cFluor R668 cFluor R720 Instruments cFluor R780 ViaDye Red cFluor R840 Applications Instruments Bioinformatics Services Clinical Reagents Software Hu DOOD மிம் CYTEK FULL SPECTRUM 5-LASER CYTOMETRY AT A GLANCE — chan mi CYTEK CYTEK CYTEK Dimensionality Reduction CYTEK 5#6Global Scale and Reach with Diversified Revenue Mix (1) Since Launch of Aurora Series in 2017... 1,500+ Customers 150+ Biopharma Companies 70+ -700 Employees WW Applications, Services & Sales % Revenue by Industry 59% Countries 41% Academic and Government-Owned Institutions Pharma and Biotech, Distributors and CROS CYTEK TRANSCEND THE CONVENTIONAL 1. As of Q3'23 Seattle Fremont (Headquarters) San Diego Bethesda USA 56% Amsterdam % LTM Revenue by Region (Q3'23) EMEA 25% APAC 15% Wuxi Shanghai Other Tokyo 4% SO#7Cytek Technology Enables Applications; >1,450 FSP Peer Reviewed Publications Total Peer Reviewed Scientific Publication by Application 13.30% 23.30% O 20.40% 25.80% 17.20% CYTEK TRANSCEND THE CONVENTIONAL ■ Oncology ■ Vaccines/Viral infection ■ Immunology/Therapies ■ Inflammation/Autoimmunity 1 Drug Development/other Cella Cancer Research AAGR JCI insIGHT www Temer specie stress drives unique pattern of resistance to immag The Journal of Immunology Why Customers Choose Cytek nature INSIDE GREEN FLUORESCENT PROTEIN Science Advances MAAAS Deeper assessment of patient immune status - before and after treatment Maximize the value of a lab sample with more information in less time with fewer errors .LO Fully Standardized across experiments and laboratory sites. More powerful system at a lower cost with minimal learning curve 7#8Muse T-cell isolation Muse easyCyte Northern Lights T-cell activation Application Examples for Life-Saving Therapies Leukapheresis Aurora Northern Lights ImageStream easyCyte T-cell Engineering/Transduction C Come Muse easyCyte Aurora CYTEK TRANSCEND THE CONVENTIONAL Instruments Northern Lights Applications Bioinformatics Clinical MRD (Minimal Residual Disease) Aurora Northern Lights easyCyte Lot release prior to infusion / QA Muse easyCyte Northern Lights Cancer kill assay Aurora Northern Lights ImageStream easyCyte Modified T-cell expansion Muse easyCyte Aurora Northern Lights Needs We Address: Data Reproducibility & Quality, Standardization, Automation, Deep Phenotyping CS Sorter 80#9Al Based Imaging Cell Analysis Enables New Therapies Cytek ImageStream ImageStream Mk Il CYTEK TRANSCEND THE CONVENTIONAL amnis Luminex FDA U.S. FOOD & DRUG ADMINISTRATION +Home / News & Events / FDA Newsroom / Press Announcements / FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease FDA NEWS RELEASE FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease Normal Cells Sickle Cells#10Focus Relentlessly on Cutting-Edge Applications Immunotherapy Immuno-oncology Immune-profiling CAR-T cells Cytek Instrument and Reagent Strategy Drives Growth 1,450+ FSP publications in many application areas Instruments CYTEK TRANSCEND THE CONVENTIONAL Position the platform Pharma, Biotech & CROS Instruments at top pharma and CRO companies Applications Cytek cFluor and Tonbo reagents and panels Bioinformatics Translate applications into Clinical Space Immunotherapy monitoring Minimal Residual Disease Clinical Infectious disease Expanded KOL partnerships & collaborations / Cytek Continued Progress Transforming Cytek to a Full Solutions Provider Kits & Panels Clinical & Research assays IVD product registrations completed or in Cytek proprietary cFluor FSP enabler reagent Combining instrument and reagents knowledge to enable HD cell analysis panel Cloud based experiment and panel design 10#11Functionalities Panel Design Experimental Design Cloud-Based Operating System for Cytek Cell Analysis Platform Integrated End-to-End Solution Expected to Accelerate Adoption Data Analysis CYTEK TRANSCEND THE CONVENTIONAL NA WX ****** Data Storage and User Management Instruments B Applications Bioinformatics Clinical Cytek investing in cloud capability to support growing customer base 11#12CYTEK™ NL-3000 O Full Spectrum Profiling Instruments FSP Technology Enables Comprehensive Clinical Applications and Lower Cost Advanced Flow Cytometry for Disease Screening, Diagnosis and Monitoring CYTEK TRANSCEND THE CONVENTIONAL Applications Bioinformatics Clinical Benefits of Cytek FSP Technology for Clinical Use Single Tube Increases Sensitivity e.g., MRD Eliminates Redundant Reagents and Lowers Costs Identifies Rare Populations of Abnormal Cells Optimizes Use of Smaller Amounts of Patient Specimen Opens Up Opportunities for New Dx Applications 12#13Cytek's 2024 Operational and Shareholder Goals Cost and Capital Efficiency Operational Excellence. Maximize Free Cash Flow CYTEK TRANSCEND THE CONVENTIONAL Commitment to Shareholder Value Creation Profitable Growth Execution Speed Smart Acquisitions 13#14CYTEK TRANSCEND THE CONVENTIONAL (R) Thank You#15CYTEK TRANSCEND THE CONVENTIONAL Appendix R#16GAAP to Non-GAAP (GP and EBITDA) September 30, 2023 (In thousands) GAAP gross profit Stock Based Compensation Amortization of acquisition-related Intangib Non-GAAP Gross Profit GAAP gross profit % Non-GAAP gross profit % GAAP Net (loss) income Depreciation and Amortization Provision (Benefit) for Tax Interest Income Interest Expense Foreign Currency exchange loss Loss on lease exit cost Stock Based Compensation Acquisition related expenses Adjusted EBITDA CYTEK TRANSCEND THE CONVENTIONAL $ $ $ $ 27,178 $ 829 458 28,465 $ 57% 59% (6,456) $ 2,561 2,271 (1,622) 595 613 5,758 3,720 $ June 30, 2023 28,162 $ 868 539 29,569 $ 57% 60% (4,388) $ 2,445 (2,207) (1,201) 409 535 5,922 27 1,542 $ March 31, December 31, 2023 21,038 $ 692 223 21,953 $ 57% 59% (6,807) $ 1,801 (2,233) (2,143) 673 (1) 4,699 1,485 (2,526) $ 2022 September 30, 2022 29,374 $ 640 65 30,079 $ 61% 62% 3,718 $ 1,465 396 (2,626) 687 (1,748) 4,465 218 6,575 $ 26,862 $ 759 64 27,685 $ 66% 68% 1,626 $ 1,452 224 (1,584) 649 570 4,359 7,296 $ June 30, 2022 24,561 $ 749 64 25,374 $ 61% 63% (702) $ 1,356 (699) (391) 647 331 3,934 4,476 $ March 31, 2022 December 31, 2021 20,177 $ 707 57 20,941 $ 58% 60% (2,158) $ 1,294 (1,145) (18) 590 422 3,837 2,822 $ September 30, 2021 23,636 $ 717 50 24,403 $ 61% 63% (1,165) $ 685 1,609 (18) 492 295 347 3,008 230 5,483 $ 21,277 $ 559 21,836 $ 62% 64% 1,420 $ 189 655 (12) 441 388 2,455 5,536 $ June 30, 2021 19,745 $ 120 19,865 $ 65% 65% 2,670 $ 201 597 (9) 433 135 667 4,694 $ March 31, 2021 14,486 112 14,598 60% 60% 102 167 50 (10) 375 663 456 1,803 16